Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.5%

4 terminated out of 47 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

22%

4 of 18 completed with results

Key Signals

4 with results82% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (9)
Early P 1 (1)
P 1 (13)
P 2 (7)
P 3 (1)

Trial Status

Completed18
Recruiting15
Terminated4
Unknown4
Not Yet Recruiting3
Active Not Recruiting1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT07262983Phase 1Recruiting

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT03952624Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

NCT07598396Phase 2RecruitingPrimary

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

NCT06999109Not ApplicableNot Yet RecruitingPrimary

Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress

NCT06013995Phase 1CompletedPrimary

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

NCT07602595Recruiting

The BRIDGE Pain Study

NCT05612750Not ApplicableRecruiting

Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study

NCT03093402Phase 2Completed

JBT-101 in Systemic Lupus Erythematosus (SLE)

NCT04334031Not ApplicableRecruiting

Deployment o the Multidisciplinary Prospective Cohort Imminent

NCT07128966Recruiting

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07302113Not ApplicableRecruitingPrimary

Complete Cognitive Intervention for cSLE

NCT06434363Phase 1Recruiting

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06839976Phase 1Recruiting

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT07134166Not Yet RecruitingPrimary

Cardiac Imaging in Systemic Disorders: the ORACLES Registry

NCT07267091CompletedPrimary

The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study

NCT04806620Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT07282392Not ApplicableRecruitingPrimary

Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)

NCT07107659Early Phase 1Recruiting

Safety and Efficacy of ONT01 in Lupus

NCT05715463Not ApplicableActive Not Recruiting

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT06752876Phase 1Withdrawn

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Scroll to load more

Research Network

Activity Timeline